Myriad Genetics, Inc. MYGN

Health CareHealthcare Equipment & SuppliesUnited States of America

Last close 6.04 USD on Nov 3, 2026, −1.8% year to date

Quant rating

Quant rating C Rank 314 of 565 in Health Care

Growth C 371 of 565
Valuation D 511 of 565
Quality B 93 of 565
Revisions D 496 of 565
Momentum C 233 of 565

Wall Street consensus Hold (3.22)Average target 4.49 USD −25.7%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 578M
Enterprise value: 583M
52-week range: 2.74 – 8.09
3-year range: 2.74 – 28.60
Dividend yield: –
Beta (5 years): 1.61
Shares outstanding: 95.6M
Next earnings: Nov 4, 2026

About the company

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

Growth and profitability

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	824	838	753	678	691	–
Revenue growth	−1.6%	11.2%	11.0%	−1.8%	130.4%	22.4%
EPS (basic, normalized)	0.06	0.14	−0.27	−0.30	0.02	–
EPS growth	−57.1%	–	–	–	–	–
Gross margin	69.9%	69.9%	68.6%	70.2%	71.4%	70.0%
Net margin	−44.4%	−15.2%	−35.0%	−16.5%	−3.5%	−22.9%
ROE	−68.5%	−17.2%	−31.6%	−12.1%	−2.7%	−26.4%

Balance sheet, last quarter
Cash & short-term investments (mil)	115
Current ratio	2.21x
Long-term debt (mil)	121
Net debt (mil)	5.5
Total equity (mil)	304
Net debt / equity	0.02x
Net debt / EBITDA	0.14x

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	824	−1.6%	0.7x	38.9	+2.6%	15.0x	0.06	−57.1%	100.7x
2026	778	−5.6%	0.7x	−52.7	−235.4%	−11.1x	−0.74	−1,331.5%	−8.2x
2027	820	+5.5%	0.7x	−34.8	+33.9%	−16.7x	−0.59	+20.3%	−10.3x
2028	876	+6.8%	0.7x	21.8	+162.6%	26.8x	−0.31	+47.4%	−19.5x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	778	0.0%	−0.1%	−10.0%	−0.74	0.0%	−7.7%	−1,639.4%
2027	820	−0.1%	−0.5%	−10.2%	−0.59	−1.1%	−18.3%	−462.0%
2028	876	0.0%	−3.0%	−9.1%	−0.31	+0.4%	−21.1%	−219.8%

Earnings surprises EPS beat in 1 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	202	212	213	211	196	213	206	210	200	191
Sales mean (mil)	194	205	211	212	201	202	205	207	202	206
Surprise	+4.5%	+3.2%	+1.2%	−0.5%	−2.3%	+5.6%	+0.4%	+1.2%	−1.0%	−7.4%
EPS reported	−0.01	0.05	0.06	0.03	−0.03	0.05	0.00	0.04	−0.09	−0.25
EPS mean	−0.10	−0.01	0.02	0.03	−0.06	−0.01	−0.01	−0.01	−0.07	−0.06
Surprise	+90.5%	−508.8%	+211.4%	−1.0%	+48.9%	−638.2%	+100.0%	−373.6%	−31.5%	−331.9%

Peer comparison Healthcare Equipment & Supplies

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
MYGN Myriad Genetics, Inc.	578M	0.14x	−44.4%	1.90x	−8.2x	−10.3x	−11.1x	−16.7x
TMO Thermo Fisher Scientific Inc.	258.7B	3.18x	15.0%	4.73x	27.6x	25.1x	23.5x	21.8x
DHR Danaher Corporation	161.9B	2.71x	14.7%	3.02x	26.8x	24.7x	21.7x	20.0x
BDX Becton Dickinson and Co	54.0B	2.03x	7.7%	2.21x	15.6x	14.9x	11.5x	11.5x
A Agilent Technologies Inc	49.5B	1.09x	18.8%	6.72x	28.3x	26.1x	23.0x	21.3x
WAT Waters Corp	45.2B	3.88x	20.3%	2.97x	31.5x	27.9x	23.0x	20.9x
Mean		2.17x	5.3%	3.59x	20.3x	18.1x	15.3x	13.1x
Median		2.37x	14.8%	3.00x	27.2x	24.9x	22.3x	20.4x

Technical analysis

1M+33.0%
3M+100.0%
1Y−26.2%
3Y−64.5%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, Myriad Genetics, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	824	838	753	678	691	300
Cost of revenue	248	252	236	202	198	91.4
Gross profit	577	585	517	476	493	208
Selling, general & administrative expenses	538	560	565	515	538	257
Research & development	107	113	88.7	85.4	81.9	35.8
Interest expense (income), operating	–	–	–	–	–	–
Unusual expense (income)	319	33.3	120	16.9	−76.7	0
Other operating expenses	0	0	0	0	0	3.5
Operating income	−387	−121	−257	−141	−50.0	−87.8
Net interest income (expense)	−8.7	−1.1	−0.4	−0.6	−5.9	−5.1
Gain (loss) on sale of assets	–	–	–	–	−0.6	–
Other non-operating income (expense)	0.8	−1.1	−4.4	0.6	−0.6	−1.2
Net income before taxes	−395	−124	−262	−141	−57.1	−94.1
Provision for taxes	−29.2	3.8	1.1	−28.6	−32.6	−20.3
Minority interest	–	–	–	–	0	0
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	−366	−127	−263	−112	−24.5	−73.8
Extraordinary items	–	–	–	–	−2.7	20.7
Net income	−366	−127	−263	−112	−27.2	−53.1
EBIT, normalized	−67.8	−88.0	−137	−124	−127	−87.8
EBITDA, normalized	−13.6	−26.4	−75.0	−71.0	−63.9	−52.0
Basic EPS, normalized	0.06	0.14	−0.27	−0.30	0.02	–

Balance sheet in millions of USD, fiscal years

Balance sheet, Myriad Genetics, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	150	102	141	115	340	151
Receivables	115	121	114	102	91.3	91.5
Total inventory	30.6	27.5	22.0	20.1	15.3	27.1
Prepaid expenses	35.4	38.3	36.4	38.0	38.4	120
Other current assets	1.7	8.6	0	0	0	0
Total current assets	333	298	314	275	485	389
Property, plant & equipment	163	172	181	187	125	100
Goodwill	51.6	286	287	287	239	329
Intangibles	153	262	350	380	404	576
Long-term investments	–	–	0	54.8	59.0	21.0
Note receivable	–	–	–	–	–	–
Other long-term assets	5.6	8.5	15.4	15.5	8.3	2.3
Total assets	707	1,028	1,146	1,199	1,321	1,419
Liabilities
Accounts payable	30.0	32.3	25.8	28.8	29.6	20.5
Payable/accrued	–	–	–	–	–	–
Accrued expenses	82.7	111	105	79.4	146	70.0
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	–	–	–	–	–	–
Other current liabilities	21.1	21.1	25.3	29.0	28.5	55.4
Total current liabilities	134	164	156	137	204	146
Long-term debt	120	39.6	38.5	0	0	225
Minority interest	–	–	–	0	0	–
Other liabilities	84.9	123	169	176	149	167
Total liabilities	339	326	363	313	353	538
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	0.9	0.9	0.9	0.8	0.8	0.8
Additional paid-in capital	1,489	1,458	1,416	1,260	1,226	1,110
Retained earnings (accumulated deficit)	−1,123	−757	−630	−366	−254	−227
Treasury stock	–	–	–	–	–	–
Other equity	0.8	−0.8	−3.7	−8.9	−5.1	−2.3
Total equity	368	701	783	886	968	881
Total liabilities & shareholders' equity	707	1,028	1,146	1,199	1,321	1,419

Cash flow statement in millions of USD, fiscal years

Cash flow statement, Myriad Genetics, Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	−366	−127	−263	−112	−27.2	−53.1
Depreciation, depletion & amortization	53.7	61.2	61.9	52.7	62.8	35.8
Deferred taxes	0.1	−2.8	−4.0	−30.8	−32.1	44.2
Non-cash items	333	115	83.8	85.3	−106	31.2
Changes in working capital	−19.3	−54.4	10.7	−102	120	−132
Cash from operations	1.8	−8.7	−111	−106	18.2	−73.7
Investing activities
Capital expenditures	−27.4	−29.7	−73.3	−45.3	−18.0	−7.9
Other investing cash flows	0	17.8	105	−32.2	292	35.9
Cash from investing	−27.4	−11.9	31.9	−77.5	274	28.0
Financing activities
Financing cash flow items	−16.1	0	−1.7	−3.7	−4.5	−0.1
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	80.3	−7.4	155	−4.3	−146	−2.0
Cash from financing	64.2	−7.4	153	−8.0	−151	−2.1
Foreign exchange effects	0.8	−1.0	0.6	−0.6	−0.6	1.1
Net change in cash	39.4	−29.0	74.5	−192	141	−46.7
Free cash flow	−25.6	−38.4	−184	−152	0.2	−81.6

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 3, 2026 after market close.